The Bochum Optimizing Clopidogrel-Aspirin Therapy and MORTality Study (BOCLA-Mort)
NCT01796691 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2013-02-26
Summary
Comparing standard treatment versus optimized antiplatelet therapy and outcomes measures.
Conditions
Sponsors & Collaborators
-
Ruhr University of Bochum
lead OTHER
Principal Investigators
-
Horst Neubauer, MD · Ruhr-University Bochum, Cardiovascular Center
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-01-31
- Primary Completion
- 2013-02-28
- Completion
- 2013-02-28
Countries
- Germany
Study Locations
More Related Trials
-
Studying the Efficacy of Aspirin & Clopidogrel in Healthy Subjects With Stable Coronary Artery Disease.
NCT01011257 ·Status: WITHDRAWN ·Phase: PHASE4
-
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)
NCT00050817 ·Status: COMPLETED ·Phase: PHASE3
-
Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
NCT00335452 ·Status: COMPLETED ·Phase: PHASE3
-
Clopidogrel Resistance and the Possibility of Its Affection
NCT00839345 ·Status: TEMPORARILY_NOT_AVAILABLE
-
Clopidogrel Efficacy and Acute Coronary Syndromes
NCT00839267 ·Status: COMPLETED
-
75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)
NCT00140465 ·Status: COMPLETED ·Phase: PHASE4
-
Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition
NCT01582217 ·Status: COMPLETED
-
Clopidogrel/Aspirin Interaction Study
NCT01102439 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
NCT00386191 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Clopidogrel Loading and Risk of PCI
NCT00457236 ·Status: UNKNOWN
-
Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients
NCT01779401 ·Status: COMPLETED ·Phase: NA
-
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD
NCT06714526 ·Status: RECRUITING ·Phase: NA
-
Anticoagulation in Stent Intervention
NCT01141153 ·Status: UNKNOWN ·Phase: PHASE4
-
Resistance to Antithrombotic Therapy
NCT00858715 ·Status: COMPLETED ·Phase: NA
-
Comparison of the Antiplatelet Efficacy of Aspirin Combined With Clopidogrel and Aspirin Combined With Half-dose Ticagrelor in Patients With Unruptured Intracranial Aneurysms With Normal CYP2C19 Metabolizer Phenotype
NCT06486363 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Anti-Platelet Drugs and Brain-derived Neurotrophic Factor (BDNF) in Human Serum and Plasma
NCT01264640 ·Status: UNKNOWN ·Phase: NA
-
Ticagrelor Versus Clopidogrel in Carotid Artery Stenting
NCT02677545 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)
NCT01294462 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacodynamic Study of Cilostazol in Healthy Volunteers
NCT02554721 ·Status: COMPLETED ·Phase: PHASE1
-
Residual Platelet Reactivity in Patients on Antiplatelet Therapy After Carotid Angioplasty With Stenting
NCT01449617 ·Status: UNKNOWN
-
Optimal Regimen in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance
NCT01925872 ·Status: UNKNOWN
-
SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3
NCT04418479 ·Status: COMPLETED ·Phase: PHASE4
-
Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients Trial
NCT03431142 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Low-dose Ticagrelor
NCT03381742 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effect of Different Anti-platelet Strategies on the Long-term Outcome After Sirolimus Drug-eluting Stent Implantation
NCT01233167 ·Status: UNKNOWN ·Phase: NA